COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Protocol No
NOVARTIS-CJBH492A12101
Principal Investigator
Timothy Fenske
Phase
I
Summary
JBH492 is an antibody drug conjugate (ADC), which means it is an antibody (protein which binds to a specific protein in the body) attached to another drug or “conjugate”. The conjugate is usually a drug that has activity against cancer, and in the case of JBH492 it is a cancer cell-killing drug called DM4.
Description
The purpose of this clinical research study is to identify an appropriate safe dose of JBH492 that can be given to patients with NHL or CLL who did not improve after treatment with currently available therapies, have had their disease worsen, and/or cannot tolerate currently available therapies. This study will also evaluate how well JBH492 might work in treating your disease and will give us an understanding how your body responds to the study treatment. In order to achieve this, a number of blood and tissue samples will be collected during the study.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL